Sarah Pringle is a senior reporter focused on M&A, private equity and auctions in the healthcare industry. Prior to joining The Deal, Pringle reported on U.S. and Canadian equity markets at Bloomberg News in New York and MarketWatch in San Francisco.
Recent Articles By The Author
Medivation Scores Premium in Sale to Pfizer
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Why Allergan is Fine Without Large M&A
The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.
Glaucoma Treatment Maker a $95M "Stepping Stone" for Allergan
The deal for ForSight VISION5 aligns with the bolt-on M&A strategy described by CEO Brent Saunders earlier this week.
Why Hendrickson-Led Perrigo Is A Good Bet For Long Term Investors
Despite cutting its full year guidance, the company continues to have a lot of potential upside.
Press Ganey to Change Hands Months After IPO
Despite a seemingly meager premium on the $2.35 billion deal, seller Vestar likely fared well after the healthcare technology company's stock appreciated more than 60% over the past 15 months.